alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Institut Jules Bordet
Brussels, Belgium
Alain Hendlisz, MDRecruiting - Uz Antwerpen
Edegem, Belgium
Hans Prenen, MDRecruiting - Uz Leuven
Leuven, Belgium
Eric Van Cutsem, MDRecruiting
- Moffit Cancer Center
Tampa, Florida, United States
Kim Dae WonNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Nov 2018
- Primary completion
- 28 Nov 2021
- Completion
- 17 Feb 2036
- Last update posted
- 20 Nov 2020
- Registered enrollment
- 49
- Registry id
- NCT03692429
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.